Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Brief Summary: The purpose of this study is to evaluate the safety and optimal dose of PCAR-119 in patients who are going to receive stem cell transplantation but without available treatment to achieve complete remission prior to the transplant.


Options:
A: Arm Label: AUTO3; Type: EXPERIMENTAL; Interventions: Biological: AUTO3 | Intervention Type: BIOLOGICAL; Name: AUTO3; Assigned to Arm(s): AUTO3
B: Arm Label: CAR-NK Cell immunotherapy; Type: EXPERIMENTAL; Interventions: Biological: anti-CD19 CAR-NK cells | Intervention Type: BIOLOGICAL; Name: anti-CD19 CAR-NK cells; Assigned to Arm(s): CAR-NK Cell immunotherapy
C: Arm Label: ALL (high tumor burden) dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (high tumor burden) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (high tumor burden) dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (low tumor burden) dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (low tumor burden) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL (ibrutinib) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL (dose dense) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Intervention Type: BIOLOGICAL; Name: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes; Assigned to Arm(s): ALL (high tumor burden) dose level 1, ALL (high tumor burden) dose level 2, ALL (high tumor burden) dose level 3, ALL (low tumor burden) dose level 1, ALL (low tumor burden) dose level 2, CLL (ibrutinib) dose level 2, CLL dose level 1, CLL dose level 2, CLL dose level 3, NHL (dose dense) dose level 2, NHL dose level 1, NHL dose level 2, NHL dose level 3
D: Arm Label: IL-2 programmed CD19.CAR-T cells; Type: EXPERIMENTAL; Interventions: Drug: CD19.CAR-T cells | Arm Label: IL-7/IL-15 programmed CD19.CAR-T cells; Type: EXPERIMENTAL; Interventions: Drug: CD19.CAR-T cells | Intervention Type: DRUG; Name: CD19.CAR-T cells; Assigned to Arm(s): IL-2 programmed CD19.CAR-T cells, IL-7/IL-15 programmed CD19.CAR-T cells

Answer: B